View Older Stories View More Recent Stories
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
Tempus AI (TEM) Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
-
ROSEN, A LEADING LAW FIRM, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
ROSEN, NATIONALLY REGARDED INVESTOR RIGHTS COUNSEL, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
TD Cowen Defends Tempus AI Inc (TEM): 'Stock Reaction Looks Overdone'
-
Tempus AI (TEM) Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
-
Tempus AI (TEM) Mentioned as Short at Spruce Point
-
Tempus AI (TEM) Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
-
Tempus AI (TEM) Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
-
Morgan Stanley on Tempus AI Inc (TEM): 'Solid Start to the Year'
-
Tempus AI, Inc (TEM) Tops Q1 EPS by 2c
-
Tempus AI (TEM) Introduces Loop
-
Tempus AI (TEM) Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
-
BTIG Starts Tempus AI Inc (TEM) at Buy
-
Illumina (ILMN) and Tempus (TEM) partner to drive the future of precision medicine through genomic AI innovation
-
Tempus AI (TEM) to acquire Deep 6 AI
-
Stifel Reiterates Hold Rating on Tempus AI Inc (TEM)
-
Tempus AI (TEM) Files for 4.84M Share Offering by Selling Stockholders
-
JPMorgan Downgrades Tempus AI Inc (TEM) to Neutral
-
After-hours movers: Zoom, Hims & Hers Health, Tempus AI, and more
-
Tempus AI, Inc (TEM) Reports Q4 Loss of $0.18
-
Tempus AI (TEM) call put ratio 1.6 calls to 1 put into quarter results and outlook
-
Tempus AI (TEM) call put ratio 1.4 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 2.3 calls to 1 put into quarter results
-
Tempus AI (TEM) and Stemline Therapeutics Collaborate to Implement Tempus Next
-
Tempus AI (TEM) call put ratio 1.9 calls to 1 put into quarter results
-
Ares Management (ARES) provides Tempus with total debt package of $560 million
-
Increasing unusual put option volume: GDDY SMMT FITB AUR TXRH VTRS MNST SATS KC TEM TWLO
-
Increasing unusual call option volume: EWW CRSR CENX BROS IAU TEM
-
Tempus AI stock downgraded by William Blair after massive rally
-
William Blair Downgrades Tempus AI Inc (TEM) to Market Perform
-
Increasing unusual put option volume: FMC EA HBAN TPX ICE EXE TKO BBAI MTCH TEM
-
Increasing unusual call option volume: DINO BCRX FMC ACB EA VSH TEM GPRO SAN JCI
-
TD Cowen Reinstates Tempus AI Inc (TEM) at Buy
-
Tempus AI (TEM) call put ratio 3.1 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 5.5 calls to 1 put with a focus on July 70 calls into quarter results
-
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways (TEM)
-
Increasing unusual put option volume: EWC EA YOU XLI EDR MLCO BTG HIMX VERU ALK TKO TEM
-
Tempus AI (TEM) call put ratio 3 calls to 1 put with as share price up 39%
-
Increasing unusual put option volume: LW FTAI WMB WEN XP FAST CFG RGTI CLMT IYR TEM
-
Tempus AI (TEM) Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
-
Tempus AI (TEM) Announces the National Launch of FDA-Approved xT CDx Test
-
Tempus AI Inc (TEM) PT Lowered to $52 at Loop Capital
-
Tempus AI (TEM) Announces xH
-
Tempus AI (TEM) Announces Preliminary Fourth Quarter and Full Year 2024 Results
-
Tempus AI (TEM) Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
-
Tempus AI Inc (TEM) PT Raised to $70 at Piper Sandler
-
Stifel Downgrades Tempus AI Inc (TEM) to Hold

